NSCLC

This phase 3 study compares the experimental drug poziotinib to the standard chemotherapy docetaxel in 268 people with advanced non-small cell lung cancer that has a specific HER2 mutation. Participants must have already tried at least one prior treatment. The main goal is to see…

This trial aimed to test a new treatment for advanced lung cancer using specially grown immune cells (LC-CTLs) designed to attack cancer. The study was withdrawn before enrolling any participants, so no results are available. It was planned as an early safety and lab-effectivenes…

This study tests whether combining two drugs, osimertinib and S-1, can shrink tumors in people with a specific type of lung cancer (EGFR mutant) that has stopped responding to standard treatments. About 30 adults with advanced lung cancer will receive the combination and be monit…

This study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for saf…

This phase II trial tests whether adding the immunotherapy drugs atezolizumab (with or without tiragolumab) to standard chemoradiotherapy can help people with stage III lung cancer that cannot be removed by surgery. About 178 participants will receive the drugs before, during, an…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This study tests a new drug called EIK1001 combined with standard treatments (pembrolizumab and chemotherapy) in 70 people with stage 4 non-small cell lung cancer who haven't had prior treatment. The main goal is to check safety and side effects, while also seeing how well the tu…

This early-phase trial tests whether adding low-dose radiation and targeted radiation (SBRT) to an immunotherapy drug (PD-1 inhibitor) is safe for people with stage IV non-small cell lung cancer who have not responded to standard treatments. About 9 participants will receive the …

This study tests whether adding the drug durvalumab to targeted radiation (SBRT) can help keep early-stage non-small cell lung cancer from coming back. It included 13 people with stage I to IIIA disease. The main goal was to see how long they lived without their cancer getting wo…

This phase 2 trial tests giving chemotherapy (carboplatin and paclitaxel) plus the immunotherapy drug nivolumab before surgery for people with Pancoast tumors, a rare type of lung cancer. After surgery, additional treatment is tailored based on whether the tumor was fully removed…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study tests a daily pill called lazertinib in 150 people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see how well the drug controls the cancer and delays its growth, while also checking for side effects. Participants have not had…

This study tests whether giving the immunotherapy drug serplulimab together with chemotherapy before surgery can help shrink non-small cell lung cancer and improve outcomes. About 36 adults with stage IIA to IIIB lung cancer will receive the combination, then have surgery to remo…

This Phase 3 study is testing whether a combination of three drugs—datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin—works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that does not h…

This study looks at using radiofrequency ablation (RFA) — a procedure that uses heat to destroy tumors — to treat lung cancer or tumors that have spread to the lungs. It is for patients who cannot have surgery due to other health issues. The goal is to see if RFA can control tumo…

This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…

This study tests whether adding a special type of radiation to standard immunotherapy before surgery can help prevent lung cancer from coming back. About 90 people with stage III lung cancer that has spread to lymph nodes will receive chemotherapy, then immunotherapy plus radiati…

This study allows people with certain cancers (NSCLC, ALCL, IMT) who are already benefiting from crizotinib in a previous Pfizer study to keep receiving the drug after that study ends. About 27 participants will continue treatment while doctors monitor for side effects. The goal …

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help control non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if the combinati…

This study tests an experimental oral drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific mutation in the KRAS gene (G12C). The trial aims to find the best dose and check if the drug is safe and can shrink tumors. About 315 adults whose ca…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This phase II trial tests a new drug called AK112, which targets both PD1 and VEGF, combined with standard chemotherapy in 265 people with advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination can shrink tumors and improve outcomes. Participants have …

This study tests an experimental oral drug, MRT-2359, in adults with certain advanced cancers, including lung cancer, lymphoma, and other solid tumors driven by MYC genes. The first part finds the safest dose; the second part checks if the drug shrinks tumors. About 174 participa…

This phase 2 trial tests the drug JDQ443 in people with non-small cell lung cancer before they have surgery. The goal is to see if the drug can shrink tumors and improve outcomes. Only 4 participants are enrolled, so results are very early.

This study looks at whether a blood test (liquid biopsy) can help doctors see how well the drug brigatinib is working in people with a certain type of advanced lung cancer (ALK-positive NSCLC). About 33 patients who have not had chemotherapy before will take brigatinib pills dail…

This study tests whether giving stereotactic body radiotherapy (SBRT) to growing metastatic tumors can delay overall cancer progression. About 107 adults with triple-negative breast cancer or non-small cell lung cancer that has started to grow in a few spots will receive SBRT or …

This phase 2 trial is testing whether it is safe and effective to continue the targeted therapy osimertinib while also giving radiation to areas where lung cancer has started to grow again. The study includes 42 adults with EGFR-positive non-small cell lung cancer who are already…

This phase II study is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy after lung cancer surgery can clear tumor DNA from the blood. The trial enrolls 100 patients with early-stage non-small cell lung cancer who had detectable tumor DNA after s…

This study offers continued access to the drug lorlatinib for people with a specific type of lung cancer (ALK-positive or ROS1-positive non-small cell lung cancer) who are already benefiting from it in earlier Pfizer studies. The main goal is to track long-term safety and side ef…

This study tests an experimental oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma, a type of brain cancer. The drug is designed to block specific EGFR mutations that help these cancers grow. The trial has two p…

This phase 2 study tests whether combining the immunotherapy drug durvalumab with radiation therapy (without chemotherapy) can delay cancer worsening in people with locally advanced non-small cell lung cancer. About 61 participants will receive radiation plus durvalumab infusions…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This early-stage trial tests a new drug called CLN-619, which targets specific proteins on cancer cells to help the immune system fight tumors. It is being tested alone or with another drug (pembrolizumab) in about 440 adults with advanced solid tumors that have spread. The main …

This early-phase study tests a new oral drug, furmonertinib, in 30 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Some participants have already tried other treatments, while others are newly diagnosed. The goal is to see if t…

This study tests a daily pill called furmonertinib in about 100 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already tried chemotherapy. The goal is to see if the drug shrinks tumors and how sa…

This phase 2 trial tests whether adding the immunotherapy drug cadonilimab (AK104) to standard chemoradiotherapy can improve outcomes for people with stage III non-small cell lung cancer that cannot be removed by surgery. About 41 participants will receive the drug before, during…

This study is testing a blood-based genetic test to find cancer-driving mutations in patients with lung cancer or melanoma. The goal is to see if this simple blood draw can replace the need for a tumor biopsy, which is slower and more invasive. Researchers will check how accurate…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study follows 330 people with non-small cell lung cancer who receive immunotherapy before surgery. Researchers measure cortisol levels at different times to see if changes in this stress hormone relate to how well the tumor shrinks or if side effects occur. The goal is to fi…

This study follows about 800 people with ALK-positive advanced non-small cell lung cancer who are taking the drug alectinib as part of their routine care. Researchers want to see how long the cancer stays under control and how patients are managed in real-world clinics, not just …

This 100% remote study surveys 250 people diagnosed with non-small cell lung cancer before age 50. Participants answer questions about their environment, lifestyle, and family history, and may donate blood. The goal is to uncover factors linked to genetic changes that drive young…